Effects of Treatment with Anti-immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma

DOI Web Site 被引用文献11件
  • Ratko Djukanović
    University of Southampton, Southampton; Imperial College, London; Novartis Horsham Research Centre, Horsham, United Kingdom; National Jewish Center, Denver, Colorado; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and University of California, San Francisco, San Francisco, California
  • Susan J. Wilson
    University of Southampton, Southampton; Imperial College, London; Novartis Horsham Research Centre, Horsham, United Kingdom; National Jewish Center, Denver, Colorado; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and University of California, San Francisco, San Francisco, California
  • Monica Kraft
    University of Southampton, Southampton; Imperial College, London; Novartis Horsham Research Centre, Horsham, United Kingdom; National Jewish Center, Denver, Colorado; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and University of California, San Francisco, San Francisco, California
  • Nizar N. Jarjour
    University of Southampton, Southampton; Imperial College, London; Novartis Horsham Research Centre, Horsham, United Kingdom; National Jewish Center, Denver, Colorado; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and University of California, San Francisco, San Francisco, California
  • Mark Steel
    University of Southampton, Southampton; Imperial College, London; Novartis Horsham Research Centre, Horsham, United Kingdom; National Jewish Center, Denver, Colorado; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and University of California, San Francisco, San Francisco, California
  • K. Fan Chung
    University of Southampton, Southampton; Imperial College, London; Novartis Horsham Research Centre, Horsham, United Kingdom; National Jewish Center, Denver, Colorado; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and University of California, San Francisco, San Francisco, California
  • Weibin Bao
    University of Southampton, Southampton; Imperial College, London; Novartis Horsham Research Centre, Horsham, United Kingdom; National Jewish Center, Denver, Colorado; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and University of California, San Francisco, San Francisco, California
  • Angel Fowler-Taylor
    University of Southampton, Southampton; Imperial College, London; Novartis Horsham Research Centre, Horsham, United Kingdom; National Jewish Center, Denver, Colorado; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and University of California, San Francisco, San Francisco, California
  • John Matthews
    University of Southampton, Southampton; Imperial College, London; Novartis Horsham Research Centre, Horsham, United Kingdom; National Jewish Center, Denver, Colorado; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and University of California, San Francisco, San Francisco, California
  • William W. Busse
    University of Southampton, Southampton; Imperial College, London; Novartis Horsham Research Centre, Horsham, United Kingdom; National Jewish Center, Denver, Colorado; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and University of California, San Francisco, San Francisco, California
  • Stephen T. Holgate
    University of Southampton, Southampton; Imperial College, London; Novartis Horsham Research Centre, Horsham, United Kingdom; National Jewish Center, Denver, Colorado; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and University of California, San Francisco, San Francisco, California
  • John V. Fahy
    University of Southampton, Southampton; Imperial College, London; Novartis Horsham Research Centre, Horsham, United Kingdom; National Jewish Center, Denver, Colorado; University of Wisconsin Hospital and Clinics, Madison, Wisconsin; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; and University of California, San Francisco, San Francisco, California

収録刊行物

被引用文献 (11)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ